ArticlePharmacoEconomics2026
Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.
Article in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping the NEI-VFQ-25 scores to the EQ-5D-Y-3L and CHU-9D utility values among adolescents with myopia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAn economic evaluation is widely used to facilitate decision making regarding drug reimbursement in many healthcare systems. However, the absence of preference-based measurement in clinical trials has hindered the health economic evaluation of drugs for rare diseases.
objectiveThis study aims to develop mapping algorithms that convert disease-specific scales-Spinal Muscular Atrophy Independence Scale (SMAIS) for spinal muscular atrophy and Functional Assessment of Cancer Therapy-Anemia (FACT-An) for paroxysmal nocturnal hemoglobinuria-into five-level EQ-5D (EQ-5D-5L) and SF-6D version 2 (SF-6Dv2) utility values, thereby enabling the economic evaluation of related drugs.
methodsData were collected from two online surveys conducted in China. Both direct and indirect mapping methods were explored, including ordinary least squares regression, Tobit regression model, censored least absolute deviation, generalized linear model, beta mixture regression, adjusted limited dependent variable mixture model, ordinal logistic regression (OLOGIT), and multinomial logistic regression (MLOGIT). Model performance was assessed by mean absolute error (MAE), root mean squared error (RMSE), and adjusted R-square (adjusted R
resultsA total of 192 patients with spinal muscular atrophy and 306 patients with paroxysmal nocturnal hemoglobinuria were included in the analysis. For spinal muscular atrophy, the MLOGIT, which included SMAIS total score and sex as predictors, demonstrated the best performance, with the lowest MAE and RMSE (EQ-5D-5L: MAE: 0.1471; RMSE: 0.1839; adjusted R
conclusionsThese newly developed mapping algorithms enable the estimation of EQ-5D-5L and SF-6Dv2 utilities in the absence of a preference-based measurement, thus supporting health economic evaluations of therapies for spinal muscular atrophy and paroxysmal nocturnal hemoglobinuria.
Indexed as
Identifiers
41182577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.